{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:17Z","timestamp":1791571757308,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clindermatol.2026.04.015","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:05:53Z","timestamp":1777993553000},"page":"843-846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The scientific rationale for long-acting biologics in dermatology"],"prefix":"10.1016","volume":"44","author":[{"given":"Mohamad","family":"Goldust","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2026.04.015_bib0001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/1744666X.2023.2250918","article-title":"Durability and long-term outcomes of biologic therapies in psoriasis","volume":"20","author":"Rusi\u00f1ol","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0002","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1540-9740.2003.01869.x","article-title":"Evolution of biologic therapies for the treatment of psoriasis","volume":"2","author":"Gordon","year":"2003","journal-title":"Skinmed"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0003","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0006","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1517\/14728222.2014.889686","article-title":"Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?","volume":"18","author":"Chiricozzi","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0007","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1476-5381.2010.00936.x","article-title":"Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action","volume":"161","author":"Vauquelin","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0008","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1111\/bph.16104","article-title":"The importance of binding kinetics and drug-target residence time in pharmacology","volume":"181","author":"Knockenhauer","year":"2024","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0009","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s13555-024-01253-6","article-title":"Extended half-life antibodies: a narrative review of a new approach in the management of atopic dermatitis","volume":"14","author":"Yilmaz","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0010","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1634\/theoncologist.2016-0061","article-title":"Antidrug antibody formation in oncology: clinical relevance and challenges","volume":"21","author":"van Brummelen","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0011","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2147\/PPA.S375037","article-title":"Impact of routines and rituals on burden of treatment, patient training, cognitive load, and anxiety in self-injected biologic therapy","volume":"16","author":"Coyne","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0012","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0149-2918(03)80222-9","article-title":"The impact of reducing dose frequency on health outcomes","volume":"25","author":"Richter","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0013","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v32.i8.115291","article-title":"Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn\u2019s disease in China","volume":"32","author":"Wu","year":"2026","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0014","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jth.14153","article-title":"Subcommittee on Factor VIII, Factor IX, and Rare Bleeding Disorders. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH","volume":"16","author":"Ragni","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0015","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3390\/pharmaceutics17111438","article-title":"Advances in cell-mediated drug delivery for dermatologic diseases: mechanisms and current applications","volume":"17","author":"Shqair","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0016","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1039\/C9MD00018F","article-title":"Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics","volume":"10","author":"Zorzi","year":"2019","journal-title":"Medchemcomm"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0017","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/07388551.2013.834293","article-title":"Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics","volume":"35","author":"Rath","year":"2015","journal-title":"Crit Rev Biotechnol"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0018","article-title":"PEGylated therapeutics in the clinic","volume":"9","author":"Gao","year":"2023","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0019","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/protein\/gzt023","article-title":"PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins","volume":"26","author":"Schlapschy","year":"2013","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0020","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/febs.70298","article-title":"Artificial lipidation of proteins and peptides: from mechanism to clinical applications","volume":"293","author":"Mu","year":"2026","journal-title":"FEBS J"},{"key":"10.1016\/j.clindermatol.2026.04.015_bib0021","first-page":"495","article-title":"Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review","volume":"44","author":"Khan","year":"2019","journal-title":"J Clin Pharm Ther"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26001021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26001021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:54:11Z","timestamp":1791568451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X26001021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0738081X26001021"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.04.015","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The scientific rationale for long-acting biologics in dermatology","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}